Evidence map›Paper›PMID 35842741›Full record

ReviewPhotochemistry and photobiology2023

Chemophototherapeutic Ablation of Doxorubicin-Resistant Human Ovarian Tumor Cells.

Sanjana Ghosh, Upendra Chitgupi, Ulas Sunar, Jonathan F Lovell

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Photochemistry and photobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sanjana GhoshDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY.
Upendra ChitgupiDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY.
Ulas SunarDepartment of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, OH.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY.ORCID 0000-0002-9052-884X
University at Buffalo, State University of New York · USNektar Therapeutics (United States) · USWright State University · US

Funding

Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Quantitative Fluorescence Imaging-Guided Detection and Targeted Therapy Monitoring Platform for Ovarian Cancer MicrometastasesR01CA243164 · NCI · WRIGHT STATE UNIVERSITY · PI Ulas Sunar · 2020 to 2026
$1.7M
NCI NIH HHS R01 CA243164NIBIB NIH HHS R01 EB017270
6 · The paper itself

Abstract

Porphyrin-phospholipid (PoP) liposomes loaded with Doxorubicin (Dox) have been demonstrated to be an efficient vehicle for chemophototherapy (CPT). Multidrug resistance (MDR) of cancer cells is a problematic phenomenon in which tumor cells develop resistance to chemotherapy. Herein, we report that Dox-resistant tumor cells can be ablated using our previously described formulation termed long-circulating Dox loaded in PoP liposomes (LC-Dox-PoP), which is a PEGylated formulation containing 2 mol. % of the PoP photosensitizer. In vitro studies using free Dox and LC-Dox-PoP showed that human ovarian carcinoma A2780 cells were more susceptible to Dox compared to the corresponding Dox-resistant A2780-R cells. When CPT was applied with LC-Dox-PoP liposomes, effective killing of both nonresistant and resistant A2780 cell lines was observed. An in vivo study to assess the efficiency of LC-Dox-PoP showed effective tumor shrinkage and prolonged survival of athymic nude mice bearing subcutaneous Dox-resistant A2780-R tumor xenografts when they were irradiated with a red laser. Biodistribution analysis demonstrated enhanced tumoral drug uptake in Dox-resistant tumors with CPT, suggesting that increased drug delivery was sufficient to induce ablation of resistant tumor cells.

Indexed as

LiposomesOvarian NeoplasmsAnimalsCell Line, TumorDoxorubicinFemaleHumansMiceMice, NudePhospholipidsPolyethylene GlycolsTissue DistributionDoxorubicinliposomal doxorubicinLiposomesPhospholipidsPolyethylene Glycols

Identifiers

PMID35842741
PMCPMC9841062
OpenAlexW4285677362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.